<DOC>
	<DOCNO>NCT00637949</DOCNO>
	<brief_summary>This safety study evaluate incidence gastrointestinal adverse event edema patient osteoarthritis treat lumiracoxib rofecoxib comparator</brief_summary>
	<brief_title>Safety Lumiracoxib Patients With Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Rofecoxib</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Age &gt; =50 year old Primary osteoarthritis hip , hand , knee spine least 3 month Pain target joint moderate intensity Written inform consent Secondary osteoarthritis Active upper gastro intestinal tract ulceration Inflammatory joint disease Gout Clinically significant hepatic renal disease Other exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>lumiracoxib</keyword>
	<keyword>rofecoxib</keyword>
	<keyword>Cox-2</keyword>
	<keyword>Osteoarthritis ( primary osteoarthritis hip , hand , knee spine ( cervical lumbar )</keyword>
</DOC>